History of other significant skin disease, or skin manifestations of allergic illness or other dermatologic condition, except chronic moderate or severe atopic dermatitis, that would interfere with the trial assessments or compromise the patient's safety according to the opinion of the Investigator 
Present symptoms of other skin diseases, except chronic atopic dermatitis, that could disturb the study assessment and evaluation of the skin 
Current use of any active systemic medication for chronic atopic dermatitis within one month 
Current use of active topical medication in the planned investigational area for chronic atopic dermatitis within two weeks 
History of a sunny holiday, UV-light therapy or solarium use within one month before beginning of study treatments, or planning such during the study or within 7 days after the study 
Allergy to cis-UCA, or any constituents of the placebo emulsion cream or any constituents of Protopic® ointment 
History of any skin-related cancer 
Congenital or acquired immunodeficiency or ongoing therapy that cause immunosuppression 
Earlier participation in a clinical study performed with cis-UCA 
Any clinically significant laboratory test result 
Suspected current drug or alcohol abuse 
Clinically significant illness during the 4 weeks prior to the first dose administration 
Any other condition that in the opinion of the Investigator would interfere with the evaluation of the study results or constitute a health hazard for the patient 
Unwillingness or doubtful capacity to comply with the protocol 
Doubtful availability to complete the study       
    

NCT01320579_exc_T1
Condition
skin disease
NCT01320579_exc_T2
Qualifier
significant
NCT01320579_exc_T3
Observation
History
NCT01320579_exc_T4
Condition
allergic illness
NCT01320579_exc_T5
Condition
dermatologic condition
NCT01320579_exc_T6
Condition
skin manifestations
NCT01320579_exc_T7
Scope
allergic illness or other dermatologic condition
NCT01320579_exc_T8
Condition
atopic dermatitis
NCT01320579_exc_T9
Qualifier
severe
NCT01320579_exc_T10
Qualifier
chronic moderate
NCT01320579_exc_T11
Scope
chronic moderate or severe
NCT01320579_exc_T13
Negation
except
NCT01320579_exc_T14
Condition
skin diseases
NCT01320579_exc_T15
Condition
chronic atopic dermatitis
NCT01320579_exc_T16
Negation
except
NCT01320579_exc_T17
Qualifier
could disturb the study assessment and evaluation of the skin
NCT01320579_exc_T19
Condition
chronic atopic dermatitis
NCT01320579_exc_T20
Temporal
within one month
NCT01320579_exc_T21
Drug
systemic medication
NCT01320579_exc_T22
Temporal
active
NCT01320579_exc_T23
Condition
chronic atopic dermatitis
NCT01320579_exc_T24
Temporal
within two weeks
NCT01320579_exc_T25
Drug
topical medication
NCT01320579_exc_T26
Temporal
active
NCT01320579_exc_T27
Observation
sunny holiday
NCT01320579_exc_T28
Procedure
UV-light therapy
NCT01320579_exc_T29
Observation
solarium use
NCT01320579_exc_T30
Temporal
within one month before beginning of study treatments
NCT01320579_exc_T31
Reference_point
beginning of study treatments
NCT01320579_exc_T32
Observation
planning
NCT01320579_exc_T33
Temporal
during the study
NCT01320579_exc_T34
Temporal
within 7 days after the study
NCT01320579_exc_T35
Scope
during the study or within 7 days after the study
NCT01320579_exc_T36
Scope
sunny holiday, UV-light therapy or solarium use
NCT01320579_exc_T37
Condition
Allergy
NCT01320579_exc_T38
Drug
Protopic® ointment
NCT01320579_exc_T39
Drug
cis-UCA
NCT01320579_exc_T40
Drug
placebo emulsion cream
NCT01320579_exc_T41
Scope
cis-UCA, or any constituents of the placebo emulsion cream or any constituents of Protopic® ointment
NCT01320579_exc_T42
Condition
skin-related cancer
NCT01320579_exc_T43
Observation
History
NCT01320579_exc_T44
Condition
acquired immunodeficiency
NCT01320579_exc_T45
Condition
immunodeficiency Congenital
NCT01320579_exc_T46
Procedure
therapy that cause immunosuppression
NCT01320579_exc_T47
Qualifier
that cause immunosuppression
NCT01320579_exc_T48
Condition
immunosuppression
NCT01320579_exc_T49
Temporal
ongoing
NCT01320579_exc_T51
Qualifier
clinically significant
NCT01320579_exc_T52
Procedure
laboratory test
NCT01320579_exc_T55
Condition
alcohol abuse
NCT01320579_exc_T56
Condition
drug abuse
NCT01320579_exc_T57
Observation
Suspected
NCT01320579_exc_T58
Temporal
current
NCT01320579_exc_T59
Scope
drug or alcohol abuse
NCT01320579_exc_T60
Temporal
during the 4 weeks prior to the first dose administration
NCT01320579_exc_T61
Reference_point
the first dose administration
NCT01320579_exc_T62
Condition
illness
NCT01320579_exc_T63
Qualifier
Clinically significant